LADENBURG THALM/SH SH assumed coverage on shares of Jaguar Health (NASDAQ:JAGX) in a report released on Thursday morning, The Fly reports. The brokerage issued a buy rating and a $5.00 target price on the biotechnology company’s stock.
Several other equities analysts have also recently weighed in on JAGX. Zacks Investment Research cut Jaguar Health from a buy rating to a hold rating in a report on Thursday, August 15th. ValuEngine upgraded Jaguar Health from a hold rating to a buy rating in a report on Thursday, August 1st. Finally, HC Wainwright set a $10.00 target price on Jaguar Health and gave the stock a buy rating in a report on Tuesday, July 2nd.
Shares of NASDAQ JAGX traded up $0.02 during trading on Thursday, hitting $1.33. The company had a trading volume of 1,172,425 shares, compared to its average volume of 440,586. The stock has a 50 day simple moving average of $1.36 and a 200 day simple moving average of $1.54. The firm has a market capitalization of $51.00 million, a P/E ratio of -0.01 and a beta of 0.74. Jaguar Health has a 12 month low of $1.00 and a 12 month high of $175.00. The company has a debt-to-equity ratio of 0.02, a quick ratio of 0.24 and a current ratio of 0.35.
Jaguar Health Company Profile
Jaguar Health, Inc, a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc, focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas.
Featured Article: What is Net Asset Value (NAV)?
Receive News & Ratings for Jaguar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Health and related companies with MarketBeat.com's FREE daily email newsletter.